top of page
Weiler Andreas 71661.jpeg
  • LinkedIn

Andreas Weiler

CDMO and Biopharmaceutical Manufacturing

Career Highlights

Andreas brings over 25 years of experience in the CDMO and biopharmaceutical manufacturing industry, specializing in areas like ADCs, Bioconjugates, Exosomes, recombinant Proteins, HPAPIs and Cell and Gene therapies.

  • Accompanied more than 200 clinical projects including the commercial launch of several projects.

  • Started with Sigma Aldrich (SAFC) now Merck Millipore later moved to Lonza to lead their Emerging Technology business.

  • During his time at Lonza, the world’s largest Cell & Gene Therapy facility in Houston with almost 300’000 square feet, was constructed. To further expand Lonza’s Cell & Gene footprint, Pharma Cell in Europe was acquired and a strategic collaboration with Nikon in Japan was formed this allowed Lonza to support their customers and patients with global services and solutions offering. As automation technologies are a key success factor in the Cell therapy space the automation technology “CocoonTM “was acquired.

  • During his leadership numerous strategic customer agreements were signed positioning Lonza as the number one CDMO for late phase Cell & Gene therapy projects.

  • The last 3 years Andreas worked for Novartis, leading a global team identifying new strategic external partnerships, building a reliable global network of strategic manufacturing partners. His team completely redesigned and expanded the external autologous manufacturing footprint for KymriahTM from originally 1 to 4 commercial autologous manufacturing sites in Germany, Japan, Australia and China.

  • In addition, the Viral Vector manufacturing for KymriahTM was switched to a suspension process reducing the cost by a factor 10-20.


Bachelor of Science degree in Chemistry from the RWTH in Aachen and finished his Ph.D. with Summa Cum Laude in Organic Chemistry from the University of Freiburg.

bottom of page